Market Insight - How to prevent M&A heartburn
This article was originally published in Scrip
Executive Summary
Many champions of the pharmaceutical industry achieved scale and global reach through mergers and acquisitions. Indeed, the M&A remains a robust strategy for companies of all sizes looking for innovation, greater efficiencies or commercial advantage. Yet the integration of separate organisations is fraught with challenges that can undermine the very drivers for doing the deal, explain Dorene Lynch, Greg Kain and Alvin Doss, Jr.